UC Davis A Favored Trial Site for the Pfizer BNT162b2 Booster Dose Clinical Trial

UC Davis A Favored Trial Site for the Pfizer BNT162b2 Booster Dose Clinical Trial

University of California Davis (UC Davis), a major academic research center in California’s agricultural belt adjacent to the state capitol in Sacramento, announced Pfizer selected it as a major site for a COVID-19 booster study. The trial sites will collect data from clinical trial participants to help federal authorities determine whether a booster shot is in order. UC Davis recently enrolled 60 participants who received the booster or placebo. The key question is—is it safe and effective?

In the latest phase of the trial, 60 participants at UC Davis Health recently received the third dose of either the vaccine or placebo to determine whether a booster is necessary, safe, and effective against not only the original COVID-19 but the highly infectious Delta variant. 

UC Davis representatives aren’t surprised they were selected for the booster study given their trial success over the past year, involving 225 participants from this trial site organization. Angela Haczku serves as a co-principal investigator and recently went on the record that Pfizer, the trial’s sponsor, was impressed with the “efficiency of trial participant recruiting, quality of data collection, recor...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee